A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7
|
作者：
Akaza, Hideyuki [1 ]
Uemura, Hirotsugu [2 ]
Tsukamoto, Taiji [3 ]
Ozono, Seiichiro [4 ]
Ogawa, Osamu [5 ]
Sakai, Hideki [6 ]
Oya, Mototsugu [7 ]
Namiki, Mikio [8 ]
Fukasawa, Satoshi [9 ]
Yamaguchi, Akito [10 ]
Uemura, Hiroji [11 ]
Ohashi, Yasuo [12 ]
Maeda, Hideki [13 ]
Saito, Atsushi [13 ]
Takeda, Kentaro [13 ]
Naito, Seiji [10 ]
机构：
[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan
[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan
[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan
[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan
[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan
[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan
[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan
[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan
[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan
[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan
[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan
[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan
来源：
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期
关键词：
Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;
D O I：
10.1007/s10147-016-0952-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Trial registration: ClinicalTrials.gov NCT01284920.
引用
收藏
页码：773 / 782
页数：10
相关论文
共 50 条
  • [41] Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer
    Chism, David D.
    De Silva, Dinuka
    Whang, Young E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (11) : 1369 - 1378
  • [42] US Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Ning, Yang-Min
    Brave, Michael
    Maher, V. Ellen
    Zhang, Lijun
    Tang, Shenghui
    Sridhara, Rajeshwari
    Kim, Geoffrey
    Ibrahim, Amna
    Pazdur, Richard
    ONCOLOGIST, 2015, 20 (08): : 960 - 966
  • [43] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [44] Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer
    Kato, Haruo
    Furuya, Yosuke
    Miyazawa, Yoshiyuki
    Miyao, Takeshi
    Syuto, Takahiro
    Nomura, Masashi
    Sekine, Yoshitaka
    Koike, Hidekazu
    Matsui, Hiroshi
    Shibata, Yasuhiro
    Ito, Kazuto
    Suzuki, Kazuhiro
    ANTICANCER RESEARCH, 2016, 36 (11) : 6141 - 6149
  • [45] Enzalutamide: A Review in Castration-Resistant Prostate Cancer
    Scott, Lesley J.
    DRUGS, 2018, 78 (18) : 1913 - 1924
  • [46] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [47] Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
    Li, Pei-Yu
    Lu, Ying-Hao
    Chen, Chung-Yu
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer
    Emamekhoo, Hamid
    Barata, Pedro C.
    Edwin, Natasha C.
    Woo, Kaitlin M.
    Grivas, Petros
    Garcia, Jorge A.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 429 - 436
  • [49] Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
    Thomsen, Frederik Birkebaek
    Roder, Martin Andreas
    Rathenborg, Per
    Brasso, Klaus
    Borre, Michael
    Iversen, Peter
    SCANDINAVIAN JOURNAL OF UROLOGY, 2014, 48 (03) : 268 - 275
  • [50] Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer
    Shore, Neal
    Carles, Joan
    McDermott, Ray
    Agarwal, Neeraj
    Tombal, Bertrand
    FRONTIERS IN MEDICINE, 2024, 11
12345